Skip to main content
Fig. 6 | Journal of Nanobiotechnology

Fig. 6

From: Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model

Fig. 6

Systemic immune response was measured in spleen and lymph nodes collected from B16OVA tumor bearing mice treated with saline, free Dox, Conventional Dox liposomes (LPD), LPD co-administered with 28 µg of free α-PD-L1 (mAb) or Targeted Dox liposome or immunoliposomes (LPF). Dox was intravenously injected at 3 mg/kg and eight days later, organs were removed to analyze different T cell subpopulations. a Lymphocyte activation status determination in spleen after incubation with SIINFEKL peptides (ELISPOT); b Degree of activation (Granzyme B) measured in CD8+ cells in lymph nodes after 4 h of stimulation with PMA/Ionomicin. Bars show the maximum and minimum range of data with the mean. Data belong to two independent studies involving eight mice. **p < 0.01 compared to control

Back to article page